Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide

Giovanni Palladini, Paola Russo, Francesca Lavatelli, Mario Nuvolone, Riccardo Albertini, Tiziana Bosoni, Vittorio Perfetti, Laura Obici, Stefano Perlini, Remigio Moratti, Giampaolo Merlini

Research output: Contribution to journalArticle

Abstract

Patients with primary (AL) amyloidosis and heart failure have a very poor prognosis and cannot tolerate aggressive therapy, such as autologous stem cell transplantation and high-dose dexamethasone-based regimens. We prospectively treated 22 patients with advanced cardiac amyloidosis combining oral melphalan, thalidomide, and reduced intensity dexamethasone (MTD). Six patients died due to cardiac amyloidosis before completing cycle 3. Early death was associated with reduced ejection fraction. Eight patients achieved a hematological response and four achieved a durable improvement of cardiac dysfunction. Treatment with MTD is feasible in patients with advanced cardiac AL amyloidosis and effective in subjects with preserved systolic function.

Original languageEnglish
Pages (from-to)347-350
Number of pages4
JournalAnnals of Hematology
Volume88
Issue number4
DOIs
Publication statusPublished - 2009

Keywords

  • Amyloidosis
  • Dexamethasone
  • Melphalan
  • Response
  • Thalidomide

ASJC Scopus subject areas

  • Hematology

Fingerprint Dive into the research topics of 'Treatment of patients with advanced cardiac AL amyloidosis with oral melphalan, dexamethasone, and thalidomide'. Together they form a unique fingerprint.

  • Cite this